The global Oligonucleotide Therapy-based Drug market size was estimated at USD 63950 million in 2023 and is projected to reach USD 88684.83 million by 2032, exhibiting a CAGR of 3.70% during the forecast period.
North America Oligonucleotide Therapy-based Drug market size was estimated at USD 17737.25 million in 2023, at a CAGR of 3.17% during the forecast period of 2025 through 2032.
Report Overview
Oligonucleotides can be used to modulate gene expression via a range of processes including RNAi, target degradation by RNase H-mediated cleavage, splicing modulation, non-coding RNA inhibition, gene activation and programmed gene editing.
This report provides a deep insight into the global Oligonucleotide Therapy-based Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Oligonucleotide Therapy-based Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Oligonucleotide Therapy-based Drug market in any manner.
Global Oligonucleotide Therapy-based Drug Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Sarepta Therapeutics
- Ionis Pharmaceuticals
- Alnylam
- Biogen
- Nippon Shinyaku
- Sobi
- Novartis
- BioNTech
- Pfizer
- Moderna Therapeutics
- Jazz Pharmaceuticals
- CureVac
- Regulus Therapeutics
- ProQR
- Secarna
- MiNA Therapeutics
- Sylentis
- Arrowhead
- Silence Therapeutics
- Dicerna
Market Segmentation (by Type)
- Antisense Oligonucleotides (ASO)
- siRNA
- mRNA
Market Segmentation (by Application)
- Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Oligonucleotide Therapy-based Drug Market
- Overview of the regional outlook of the Oligonucleotide Therapy-based Drug Market:
Key Reasons to Buy this Report:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Oligonucleotide Therapy-based Drug
1.2 Key Market Segments
1.2.1 Oligonucleotide Therapy-based Drug Segment by Type
1.2.2 Oligonucleotide Therapy-based Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Oligonucleotide Therapy-based Drug Market Overview
2.1 Global Market Overview
2.1.1 Global Oligonucleotide Therapy-based Drug Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Oligonucleotide Therapy-based Drug Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Oligonucleotide Therapy-based Drug Market Competitive Landscape
3.1 Global Oligonucleotide Therapy-based Drug Sales by Manufacturers (2019-2025)
3.2 Global Oligonucleotide Therapy-based Drug Revenue Market Share by Manufacturers (2019-2025)
3.3 Oligonucleotide Therapy-based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Oligonucleotide Therapy-based Drug Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Oligonucleotide Therapy-based Drug Sales Sites, Area Served, Product Type
3.6 Oligonucleotide Therapy-based Drug Market Competitive Situation and Trends
3.6.1 Oligonucleotide Therapy-based Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Oligonucleotide Therapy-based Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Oligonucleotide Therapy-based Drug Industry Chain Analysis
4.1 Oligonucleotide Therapy-based Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Oligonucleotide Therapy-based Drug Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Oligonucleotide Therapy-based Drug Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Oligonucleotide Therapy-based Drug Sales Market Share by Type (2019-2025)
6.3 Global Oligonucleotide Therapy-based Drug Market Size Market Share by Type (2019-2025)
6.4 Global Oligonucleotide Therapy-based Drug Price by Type (2019-2025)
7 Oligonucleotide Therapy-based Drug Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Oligonucleotide Therapy-based Drug Market Sales by Application (2019-2025)
7.3 Global Oligonucleotide Therapy-based Drug Market Size (M USD) by Application (2019-2025)
7.4 Global Oligonucleotide Therapy-based Drug Sales Growth Rate by Application (2019-2025)
8 Oligonucleotide Therapy-based Drug Market Consumption by Region
8.1 Global Oligonucleotide Therapy-based Drug Sales by Region
8.1.1 Global Oligonucleotide Therapy-based Drug Sales by Region
8.1.2 Global Oligonucleotide Therapy-based Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Oligonucleotide Therapy-based Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Oligonucleotide Therapy-based Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Oligonucleotide Therapy-based Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Oligonucleotide Therapy-based Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Oligonucleotide Therapy-based Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Oligonucleotide Therapy-based Drug Market Production by Region
9.1 Global Production of Oligonucleotide Therapy-based Drug by Region (2019-2025)
9.2 Global Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2019-2025)
9.3 Global Oligonucleotide Therapy-based Drug Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Oligonucleotide Therapy-based Drug Production
9.4.1 North America Oligonucleotide Therapy-based Drug Production Growth Rate (2019-2025)
9.4.2 North America Oligonucleotide Therapy-based Drug Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Oligonucleotide Therapy-based Drug Production
9.5.1 Europe Oligonucleotide Therapy-based Drug Production Growth Rate (2019-2025)
9.5.2 Europe Oligonucleotide Therapy-based Drug Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Oligonucleotide Therapy-based Drug Production (2019-2025)
9.6.1 Japan Oligonucleotide Therapy-based Drug Production Growth Rate (2019-2025)
9.6.2 Japan Oligonucleotide Therapy-based Drug Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Oligonucleotide Therapy-based Drug Production (2019-2025)
9.7.1 China Oligonucleotide Therapy-based Drug Production Growth Rate (2019-2025)
9.7.2 China Oligonucleotide Therapy-based Drug Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Sarepta Therapeutics
10.1.1 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Basic Information
10.1.2 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Overview
10.1.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Market Performance
10.1.4 Sarepta Therapeutics Business Overview
10.1.5 Sarepta Therapeutics Oligonucleotide Therapy-based Drug SWOT Analysis
10.1.6 Sarepta Therapeutics Recent Developments
10.2 Ionis Pharmaceuticals
10.2.1 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Basic Information
10.2.2 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Overview
10.2.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Market Performance
10.2.4 Ionis Pharmaceuticals Business Overview
10.2.5 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug SWOT Analysis
10.2.6 Ionis Pharmaceuticals Recent Developments
10.3 Alnylam
10.3.1 Alnylam Oligonucleotide Therapy-based Drug Basic Information
10.3.2 Alnylam Oligonucleotide Therapy-based Drug Product Overview
10.3.3 Alnylam Oligonucleotide Therapy-based Drug Product Market Performance
10.3.4 Alnylam Oligonucleotide Therapy-based Drug SWOT Analysis
10.3.5 Alnylam Business Overview
10.3.6 Alnylam Recent Developments
10.4 Biogen
10.4.1 Biogen Oligonucleotide Therapy-based Drug Basic Information
10.4.2 Biogen Oligonucleotide Therapy-based Drug Product Overview
10.4.3 Biogen Oligonucleotide Therapy-based Drug Product Market Performance
10.4.4 Biogen Business Overview
10.4.5 Biogen Recent Developments
10.5 Nippon Shinyaku
10.5.1 Nippon Shinyaku Oligonucleotide Therapy-based Drug Basic Information
10.5.2 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Overview
10.5.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Market Performance
10.5.4 Nippon Shinyaku Business Overview
10.5.5 Nippon Shinyaku Recent Developments
10.6 Sobi
10.6.1 Sobi Oligonucleotide Therapy-based Drug Basic Information
10.6.2 Sobi Oligonucleotide Therapy-based Drug Product Overview
10.6.3 Sobi Oligonucleotide Therapy-based Drug Product Market Performance
10.6.4 Sobi Business Overview
10.6.5 Sobi Recent Developments
10.7 Novartis
10.7.1 Novartis Oligonucleotide Therapy-based Drug Basic Information
10.7.2 Novartis Oligonucleotide Therapy-based Drug Product Overview
10.7.3 Novartis Oligonucleotide Therapy-based Drug Product Market Performance
10.7.4 Novartis Business Overview
10.7.5 Novartis Recent Developments
10.8 BioNTech
10.8.1 BioNTech Oligonucleotide Therapy-based Drug Basic Information
10.8.2 BioNTech Oligonucleotide Therapy-based Drug Product Overview
10.8.3 BioNTech Oligonucleotide Therapy-based Drug Product Market Performance
10.8.4 BioNTech Business Overview
10.8.5 BioNTech Recent Developments
10.9 Pfizer
10.9.1 Pfizer Oligonucleotide Therapy-based Drug Basic Information
10.9.2 Pfizer Oligonucleotide Therapy-based Drug Product Overview
10.9.3 Pfizer Oligonucleotide Therapy-based Drug Product Market Performance
10.9.4 Pfizer Business Overview
10.9.5 Pfizer Recent Developments
10.10 Moderna Therapeutics
10.10.1 Moderna Therapeutics Oligonucleotide Therapy-based Drug Basic Information
10.10.2 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Overview
10.10.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Market Performance
10.10.4 Moderna Therapeutics Business Overview
10.10.5 Moderna Therapeutics Recent Developments
10.11 Jazz Pharmaceuticals
10.11.1 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Basic Information
10.11.2 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Overview
10.11.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Market Performance
10.11.4 Jazz Pharmaceuticals Business Overview
10.11.5 Jazz Pharmaceuticals Recent Developments
10.12 CureVac
10.12.1 CureVac Oligonucleotide Therapy-based Drug Basic Information
10.12.2 CureVac Oligonucleotide Therapy-based Drug Product Overview
10.12.3 CureVac Oligonucleotide Therapy-based Drug Product Market Performance
10.12.4 CureVac Business Overview
10.12.5 CureVac Recent Developments
10.13 Regulus Therapeutics
10.13.1 Regulus Therapeutics Oligonucleotide Therapy-based Drug Basic Information
10.13.2 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Overview
10.13.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Market Performance
10.13.4 Regulus Therapeutics Business Overview
10.13.5 Regulus Therapeutics Recent Developments
10.14 ProQR
10.14.1 ProQR Oligonucleotide Therapy-based Drug Basic Information
10.14.2 ProQR Oligonucleotide Therapy-based Drug Product Overview
10.14.3 ProQR Oligonucleotide Therapy-based Drug Product Market Performance
10.14.4 ProQR Business Overview
10.14.5 ProQR Recent Developments
10.15 Secarna
10.15.1 Secarna Oligonucleotide Therapy-based Drug Basic Information
10.15.2 Secarna Oligonucleotide Therapy-based Drug Product Overview
10.15.3 Secarna Oligonucleotide Therapy-based Drug Product Market Performance
10.15.4 Secarna Business Overview
10.15.5 Secarna Recent Developments
10.16 MiNA Therapeutics
10.16.1 MiNA Therapeutics Oligonucleotide Therapy-based Drug Basic Information
10.16.2 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Overview
10.16.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Market Performance
10.16.4 MiNA Therapeutics Business Overview
10.16.5 MiNA Therapeutics Recent Developments
10.17 Sylentis
10.17.1 Sylentis Oligonucleotide Therapy-based Drug Basic Information
10.17.2 Sylentis Oligonucleotide Therapy-based Drug Product Overview
10.17.3 Sylentis Oligonucleotide Therapy-based Drug Product Market Performance
10.17.4 Sylentis Business Overview
10.17.5 Sylentis Recent Developments
10.18 Arrowhead
10.18.1 Arrowhead Oligonucleotide Therapy-based Drug Basic Information
10.18.2 Arrowhead Oligonucleotide Therapy-based Drug Product Overview
10.18.3 Arrowhead Oligonucleotide Therapy-based Drug Product Market Performance
10.18.4 Arrowhead Business Overview
10.18.5 Arrowhead Recent Developments
10.19 Silence Therapeutics
10.19.1 Silence Therapeutics Oligonucleotide Therapy-based Drug Basic Information
10.19.2 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Overview
10.19.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Market Performance
10.19.4 Silence Therapeutics Business Overview
10.19.5 Silence Therapeutics Recent Developments
10.20 Dicerna
10.20.1 Dicerna Oligonucleotide Therapy-based Drug Basic Information
10.20.2 Dicerna Oligonucleotide Therapy-based Drug Product Overview
10.20.3 Dicerna Oligonucleotide Therapy-based Drug Product Market Performance
10.20.4 Dicerna Business Overview
10.20.5 Dicerna Recent Developments
11 Oligonucleotide Therapy-based Drug Market Forecast by Region
11.1 Global Oligonucleotide Therapy-based Drug Market Size Forecast
11.2 Global Oligonucleotide Therapy-based Drug Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Oligonucleotide Therapy-based Drug Market Size Forecast by Country
11.2.3 Asia Pacific Oligonucleotide Therapy-based Drug Market Size Forecast by Region
11.2.4 South America Oligonucleotide Therapy-based Drug Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Oligonucleotide Therapy-based Drug by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Oligonucleotide Therapy-based Drug Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Oligonucleotide Therapy-based Drug by Type (2025-2032)
12.1.2 Global Oligonucleotide Therapy-based Drug Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Oligonucleotide Therapy-based Drug by Type (2025-2032)
12.2 Global Oligonucleotide Therapy-based Drug Market Forecast by Application (2025-2032)
12.2.1 Global Oligonucleotide Therapy-based Drug Sales (K MT) Forecast by Application
12.2.2 Global Oligonucleotide Therapy-based Drug Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Oligonucleotide Therapy-based Drug Market Size Comparison by Region (M USD)
Table 5. Global Oligonucleotide Therapy-based Drug Sales (K MT) by Manufacturers (2019-2025)
Table 6. Global Oligonucleotide Therapy-based Drug Sales Market Share by Manufacturers (2019-2025)
Table 7. Global Oligonucleotide Therapy-based Drug Revenue (M USD) by Manufacturers (2019-2025)
Table 8. Global Oligonucleotide Therapy-based Drug Revenue Share by Manufacturers (2019-2025)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapy-based Drug as of 2022)
Table 10. Global Market Oligonucleotide Therapy-based Drug Average Price (USD/MT) of Key Manufacturers (2019-2025)
Table 11. Manufacturers Oligonucleotide Therapy-based Drug Sales Sites and Area Served
Table 12. Manufacturers Oligonucleotide Therapy-based Drug Product Type
Table 13. Global Oligonucleotide Therapy-based Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Oligonucleotide Therapy-based Drug
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Oligonucleotide Therapy-based Drug Market Challenges
Table 22. Global Oligonucleotide Therapy-based Drug Sales by Type (K MT)
Table 23. Global Oligonucleotide Therapy-based Drug Market Size by Type (M USD)
Table 24. Global Oligonucleotide Therapy-based Drug Sales (K MT) by Type (2019-2025)
Table 25. Global Oligonucleotide Therapy-based Drug Sales Market Share by Type (2019-2025)
Table 26. Global Oligonucleotide Therapy-based Drug Market Size (M USD) by Type (2019-2025)
Table 27. Global Oligonucleotide Therapy-based Drug Market Size Share by Type (2019-2025)
Table 28. Global Oligonucleotide Therapy-based Drug Price (USD/MT) by Type (2019-2025)
Table 29. Global Oligonucleotide Therapy-based Drug Sales (K MT) by Application
Table 30. Global Oligonucleotide Therapy-based Drug Market Size by Application
Table 31. Global Oligonucleotide Therapy-based Drug Sales by Application (2019-2025) & (K MT)
Table 32. Global Oligonucleotide Therapy-based Drug Sales Market Share by Application (2019-2025)
Table 33. Global Oligonucleotide Therapy-based Drug Sales by Application (2019-2025) & (M USD)
Table 34. Global Oligonucleotide Therapy-based Drug Market Share by Application (2019-2025)
Table 35. Global Oligonucleotide Therapy-based Drug Sales Growth Rate by Application (2019-2025)
Table 36. Global Oligonucleotide Therapy-based Drug Sales by Region (2019-2025) & (K MT)
Table 37. Global Oligonucleotide Therapy-based Drug Sales Market Share by Region (2019-2025)
Table 38. North America Oligonucleotide Therapy-based Drug Sales by Country (2019-2025) & (K MT)
Table 39. Europe Oligonucleotide Therapy-based Drug Sales by Country (2019-2025) & (K MT)
Table 40. Asia Pacific Oligonucleotide Therapy-based Drug Sales by Region (2019-2025) & (K MT)
Table 41. South America Oligonucleotide Therapy-based Drug Sales by Country (2019-2025) & (K MT)
Table 42. Middle East and Africa Oligonucleotide Therapy-based Drug Sales by Region (2019-2025) & (K MT)
Table 43. Global Oligonucleotide Therapy-based Drug Production (K MT) by Region (2019-2025)
Table 44. Global Oligonucleotide Therapy-based Drug Revenue (US$ Million) by Region (2019-2025)
Table 45. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Region (2019-2025)
Table 46. Global Oligonucleotide Therapy-based Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 47. North America Oligonucleotide Therapy-based Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 48. Europe Oligonucleotide Therapy-based Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 49. Japan Oligonucleotide Therapy-based Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 50. China Oligonucleotide Therapy-based Drug Production (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2025)
Table 51. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Basic Information
Table 52. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Overview
Table 53. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 54. Sarepta Therapeutics Business Overview
Table 55. Sarepta Therapeutics Oligonucleotide Therapy-based Drug SWOT Analysis
Table 56. Sarepta Therapeutics Recent Developments
Table 57. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Basic Information
Table 58. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Overview
Table 59. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 60. Ionis Pharmaceuticals Business Overview
Table 61. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug SWOT Analysis
Table 62. Ionis Pharmaceuticals Recent Developments
Table 63. Alnylam Oligonucleotide Therapy-based Drug Basic Information
Table 64. Alnylam Oligonucleotide Therapy-based Drug Product Overview
Table 65. Alnylam Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 66. Alnylam Oligonucleotide Therapy-based Drug SWOT Analysis
Table 67. Alnylam Business Overview
Table 68. Alnylam Recent Developments
Table 69. Biogen Oligonucleotide Therapy-based Drug Basic Information
Table 70. Biogen Oligonucleotide Therapy-based Drug Product Overview
Table 71. Biogen Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 72. Biogen Business Overview
Table 73. Biogen Recent Developments
Table 74. Nippon Shinyaku Oligonucleotide Therapy-based Drug Basic Information
Table 75. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Overview
Table 76. Nippon Shinyaku Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 77. Nippon Shinyaku Business Overview
Table 78. Nippon Shinyaku Recent Developments
Table 79. Sobi Oligonucleotide Therapy-based Drug Basic Information
Table 80. Sobi Oligonucleotide Therapy-based Drug Product Overview
Table 81. Sobi Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 82. Sobi Business Overview
Table 83. Sobi Recent Developments
Table 84. Novartis Oligonucleotide Therapy-based Drug Basic Information
Table 85. Novartis Oligonucleotide Therapy-based Drug Product Overview
Table 86. Novartis Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 87. Novartis Business Overview
Table 88. Novartis Recent Developments
Table 89. BioNTech Oligonucleotide Therapy-based Drug Basic Information
Table 90. BioNTech Oligonucleotide Therapy-based Drug Product Overview
Table 91. BioNTech Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 92. BioNTech Business Overview
Table 93. BioNTech Recent Developments
Table 94. Pfizer Oligonucleotide Therapy-based Drug Basic Information
Table 95. Pfizer Oligonucleotide Therapy-based Drug Product Overview
Table 96. Pfizer Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 97. Pfizer Business Overview
Table 98. Pfizer Recent Developments
Table 99. Moderna Therapeutics Oligonucleotide Therapy-based Drug Basic Information
Table 100. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Overview
Table 101. Moderna Therapeutics Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 102. Moderna Therapeutics Business Overview
Table 103. Moderna Therapeutics Recent Developments
Table 104. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Basic Information
Table 105. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Overview
Table 106. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 107. Jazz Pharmaceuticals Business Overview
Table 108. Jazz Pharmaceuticals Recent Developments
Table 109. CureVac Oligonucleotide Therapy-based Drug Basic Information
Table 110. CureVac Oligonucleotide Therapy-based Drug Product Overview
Table 111. CureVac Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 112. CureVac Business Overview
Table 113. CureVac Recent Developments
Table 114. Regulus Therapeutics Oligonucleotide Therapy-based Drug Basic Information
Table 115. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Overview
Table 116. Regulus Therapeutics Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 117. Regulus Therapeutics Business Overview
Table 118. Regulus Therapeutics Recent Developments
Table 119. ProQR Oligonucleotide Therapy-based Drug Basic Information
Table 120. ProQR Oligonucleotide Therapy-based Drug Product Overview
Table 121. ProQR Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 122. ProQR Business Overview
Table 123. ProQR Recent Developments
Table 124. Secarna Oligonucleotide Therapy-based Drug Basic Information
Table 125. Secarna Oligonucleotide Therapy-based Drug Product Overview
Table 126. Secarna Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 127. Secarna Business Overview
Table 128. Secarna Recent Developments
Table 129. MiNA Therapeutics Oligonucleotide Therapy-based Drug Basic Information
Table 130. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Overview
Table 131. MiNA Therapeutics Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 132. MiNA Therapeutics Business Overview
Table 133. MiNA Therapeutics Recent Developments
Table 134. Sylentis Oligonucleotide Therapy-based Drug Basic Information
Table 135. Sylentis Oligonucleotide Therapy-based Drug Product Overview
Table 136. Sylentis Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 137. Sylentis Business Overview
Table 138. Sylentis Recent Developments
Table 139. Arrowhead Oligonucleotide Therapy-based Drug Basic Information
Table 140. Arrowhead Oligonucleotide Therapy-based Drug Product Overview
Table 141. Arrowhead Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 142. Arrowhead Business Overview
Table 143. Arrowhead Recent Developments
Table 144. Silence Therapeutics Oligonucleotide Therapy-based Drug Basic Information
Table 145. Silence Therapeutics Oligonucleotide Therapy-based Drug Product Overview
Table 146. Silence Therapeutics Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 147. Silence Therapeutics Business Overview
Table 148. Silence Therapeutics Recent Developments
Table 149. Dicerna Oligonucleotide Therapy-based Drug Basic Information
Table 150. Dicerna Oligonucleotide Therapy-based Drug Product Overview
Table 151. Dicerna Oligonucleotide Therapy-based Drug Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2025)
Table 152. Dicerna Business Overview
Table 153. Dicerna Recent Developments
Table 154. Global Oligonucleotide Therapy-based Drug Sales Forecast by Region (2025-2032) & (K MT)
Table 155. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Region (2025-2032) & (M USD)
Table 156. North America Oligonucleotide Therapy-based Drug Sales Forecast by Country (2025-2032) & (K MT)
Table 157. North America Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2025-2032) & (M USD)
Table 158. Europe Oligonucleotide Therapy-based Drug Sales Forecast by Country (2025-2032) & (K MT)
Table 159. Europe Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2025-2032) & (M USD)
Table 160. Asia Pacific Oligonucleotide Therapy-based Drug Sales Forecast by Region (2025-2032) & (K MT)
Table 161. Asia Pacific Oligonucleotide Therapy-based Drug Market Size Forecast by Region (2025-2032) & (M USD)
Table 162. South America Oligonucleotide Therapy-based Drug Sales Forecast by Country (2025-2032) & (K MT)
Table 163. South America Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2025-2032) & (M USD)
Table 164. Middle East and Africa Oligonucleotide Therapy-based Drug Consumption Forecast by Country (2025-2032) & (Units)
Table 165. Middle East and Africa Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2025-2032) & (M USD)
Table 166. Global Oligonucleotide Therapy-based Drug Sales Forecast by Type (2025-2032) & (K MT)
Table 167. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Type (2025-2032) & (M USD)
Table 168. Global Oligonucleotide Therapy-based Drug Price Forecast by Type (2025-2032) & (USD/MT)
Table 169. Global Oligonucleotide Therapy-based Drug Sales (K MT) Forecast by Application (2025-2032)
Table 170. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Application (2025-2032) & (M USD)
List of Figures
Figure 1. Product Picture of Oligonucleotide Therapy-based Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Oligonucleotide Therapy-based Drug Market Size (M USD), 2019-2032
Figure 5. Global Oligonucleotide Therapy-based Drug Market Size (M USD) (2019-2032)
Figure 6. Global Oligonucleotide Therapy-based Drug Sales (K MT) & (2019-2032)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Oligonucleotide Therapy-based Drug Market Size by Country (M USD)
Figure 11. Oligonucleotide Therapy-based Drug Sales Share by Manufacturers in 2023
Figure 12. Global Oligonucleotide Therapy-based Drug Revenue Share by Manufacturers in 2023
Figure 13. Oligonucleotide Therapy-based Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Oligonucleotide Therapy-based Drug Average Price (USD/MT) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Oligonucleotide Therapy-based Drug Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Oligonucleotide Therapy-based Drug Market Share by Type
Figure 18. Sales Market Share of Oligonucleotide Therapy-based Drug by Type (2019-2025)
Figure 19. Sales Market Share of Oligonucleotide Therapy-based Drug by Type in 2023
Figure 20. Market Size Share of Oligonucleotide Therapy-based Drug by Type (2019-2025)
Figure 21. Market Size Market Share of Oligonucleotide Therapy-based Drug by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Oligonucleotide Therapy-based Drug Market Share by Application
Figure 24. Global Oligonucleotide Therapy-based Drug Sales Market Share by Application (2019-2025)
Figure 25. Global Oligonucleotide Therapy-based Drug Sales Market Share by Application in 2023
Figure 26. Global Oligonucleotide Therapy-based Drug Market Share by Application (2019-2025)
Figure 27. Global Oligonucleotide Therapy-based Drug Market Share by Application in 2023
Figure 28. Global Oligonucleotide Therapy-based Drug Sales Growth Rate by Application (2019-2025)
Figure 29. Global Oligonucleotide Therapy-based Drug Sales Market Share by Region (2019-2025)
Figure 30. North America Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 31. North America Oligonucleotide Therapy-based Drug Sales Market Share by Country in 2023
Figure 32. U.S. Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 33. Canada Oligonucleotide Therapy-based Drug Sales (K MT) and Growth Rate (2019-2025)
Figure 34. Mexico Oligonucleotide Therapy-based Drug Sales (Units) and Growth Rate (2019-2025)
Figure 35. Europe Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 36. Europe Oligonucleotide Therapy-based Drug Sales Market Share by Country in 2023
Figure 37. Germany Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 38. France Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 39. U.K. Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 40. Italy Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 41. Russia Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 42. Asia Pacific Oligonucleotide Therapy-based Drug Sales and Growth Rate (K MT)
Figure 43. Asia Pacific Oligonucleotide Therapy-based Drug Sales Market Share by Region in 2023
Figure 44. China Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 45. Japan Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 46. South Korea Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 47. India Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 48. Southeast Asia Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 49. South America Oligonucleotide Therapy-based Drug Sales and Growth Rate (K MT)
Figure 50. South America Oligonucleotide Therapy-based Drug Sales Market Share by Country in 2023
Figure 51. Brazil Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 52. Argentina Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 53. Columbia Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 54. Middle East and Africa Oligonucleotide Therapy-based Drug Sales and Growth Rate (K MT)
Figure 55. Middle East and Africa Oligonucleotide Therapy-based Drug Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 57. UAE Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 58. Egypt Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 59. Nigeria Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 60. South Africa Oligonucleotide Therapy-based Drug Sales and Growth Rate (2019-2025) & (K MT)
Figure 61. Global Oligonucleotide Therapy-based Drug Production Market Share by Region (2019-2025)
Figure 62. North America Oligonucleotide Therapy-based Drug Production (K MT) Growth Rate (2019-2025)
Figure 63. Europe Oligonucleotide Therapy-based Drug Production (K MT) Growth Rate (2019-2025)
Figure 64. Japan Oligonucleotide Therapy-based Drug Production (K MT) Growth Rate (2019-2025)
Figure 65. China Oligonucleotide Therapy-based Drug Production (K MT) Growth Rate (2019-2025)
Figure 66. Global Oligonucleotide Therapy-based Drug Sales Forecast by Volume (2019-2032) & (K MT)
Figure 67. Global Oligonucleotide Therapy-based Drug Market Size Forecast by Value (2019-2032) & (M USD)
Figure 68. Global Oligonucleotide Therapy-based Drug Sales Market Share Forecast by Type (2025-2032)
Figure 69. Global Oligonucleotide Therapy-based Drug Market Share Forecast by Type (2025-2032)
Figure 70. Global Oligonucleotide Therapy-based Drug Sales Forecast by Application (2025-2032)
Figure 71. Global Oligonucleotide Therapy-based Drug Market Share Forecast by Application (2025-2032)
